NASDAQ: NXTC · Life Sciences · 7 alerts · CIK 1661059
Share price
$6.68Close, Nov 16
Market cap
$30.6M
Shares outstanding
4.58MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All NextCure, Inc. filings on SEC EDGAR ↗
NextCure Insider ADAR1 Capital Management LLC Buys $62.9K of Stock
ADAR1 Capital Management LLC bought 12,333 shares of NextCure, Inc. at $5.10 a share, worth $62.9K in total on Nov 11, 2026. Shares held after the trade: 750,289 (+1.7%).
NextCure reported a net loss of $31.5 million for the nine months ended September 30, 2026, an improvement from the $46.4 million loss in the prior year period. The company's cash position decreased significantly to $8.7 million as it underwent restructuring and asset impairment charges totaling $3.0 million.
NextCure Signs $820M M&A Deal with Avere Therapeutics, Inc.
NextCure provided a status update on its pending merger with Avere Therapeutics, noting that the SEC has declared its S-4 registration statement effective and a stockholder vote is scheduled for December 9, 2026. The transaction is supported by $820 million in committed financing from a syndicate of healthcare investors to fund the development of Avere's lead inflammatory disease program, AVR-001.
Value
$820M
Counterparty
Avere Therapeutics, Inc.
“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics. Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors. We believe this significant financing commitment reflects strong confidence in Avere's clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”